Merck KGaA Says Erbitux Fails in Stomach Cancer Trial

Merck KGaA’s Erbitux cancer treatment failed to help patients with advanced stomach tumors in a late-stage clinical trial, dealing the company a setback in the effort to expand sales of its second-biggest-selling medicine.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.